Potential Challenges in the Future Treatment of Mantle Cell Lymphoma

Rekha Rao, PhD
Published: Thursday, Apr 13, 2017



Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).

One of the biggest challenges of treating patients with MCL, says Rao, is that patients eventually develop resistance to almost all therapies.

In the case of p97 inhibitors, Rao says that there should be effort dedicated to developing newer analogs of inhibitors that can work in patients who develop resistance to existing p97 inihibitors.

Rao also proposes that the combination of p97 inhibitors with ibrutinib (Imbruvica) may hold promise for patients with relapsed MCL.
 
SELECTED
LANGUAGE


Rekha Rao, PhD, assistant professor, University of Kansas Medical Center, discusses the challenges that exist in the future of treatment for patients with mantle cell lymphoma (MCL).

One of the biggest challenges of treating patients with MCL, says Rao, is that patients eventually develop resistance to almost all therapies.

In the case of p97 inhibitors, Rao says that there should be effort dedicated to developing newer analogs of inhibitors that can work in patients who develop resistance to existing p97 inihibitors.

Rao also proposes that the combination of p97 inhibitors with ibrutinib (Imbruvica) may hold promise for patients with relapsed MCL.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x